HIGH GROWTH HOLDINGS INC

INVESTMENT PROPOSAL
www.hgh-inc.com

1 416 795 1774

erika@hgh-inc.com

TORONTO, CANADA

Advancements in medicine is generally hindered by
pharmaceutical corporate interests which limits
medicine to microscopic view of disease rather than
understanding the macrocosm of health. We offer
solutions to the problems posed by the current paradigm
of medicine through the acquiring companies whose
innovation led by cutting-edge medical science research
advances the current state of medicine through
introducing to the market novel treatments for disease
and biotech that advances the understanding of disease.
OUR
MISSION
HIGH GROWTH HOLDINGS Inc. has vested interests in
building the future of tomorrow’s through cutting-edge
scientific research that creates world-changing
innovation in life sciences and biotechnology. HGH has a
focus on companies that are pioneers through scientific
breakthrough that change the modern world or disrupt
an industry and impel its future growth. We take a firm
stance in ensuring the future is green which the
subsidiary companies play a role in by being
environmentally sustainable.
 GOALS

1 2
The goal of HIGH GROWTH HOLDINGS Inc. is We aim to build a leading corporate enterprise
to usher a brighter future for the world by through the acquisition of companies who are
introducing revolutionary innovation through radical life science leaders whose innovation
advancements within the life sciences influence markets and shape the future of
health.
 ROYAL
SYNTHESIS
ACQUISITION ROYAL SYNTHESIS is responsible for
introducing cannabis into the regulated
TARGETS
drug market and discovering the
biological mechanism which make
cannabis a panacea. The company leads
medical science research for the role the
endocannabinoid system plays in
health, disease and medicine.
NEUROMETRICS
Biotechnology that will revolutionize the
interpretation of brain wave data
collected through an EEG by harnessing
the power of A.I. The technology offers a
novel diagnostic tool to detect various
neurological and psychiatric illnesses and
is the advent to the future of gaming and
its application of using brainwaves to
enhance the gaming experience.
AVERTUS
Biotechnology that revolutionizes an EEG, making an EEG
more functional tool for the general health practitioner
through a portable EEG device. The device harness the
power of brain wave recording into biometrics that can be
used as a diagnostic tool for detecting neurological
illnesses other than epilepsy and sleep disorders along
with detection psychiatric illness. The medical diagnostic
tool allows for the general practitioner to diagnose
neurological and psychiatric illness without requiring
medical tests tor analysis from a neurologist or a
psychiatrist.
SYMCO
Biotechnology that integrates machine learning and
artificial intelligence to analyze body movement
through strength and to control movement in order
to increase increase neuronal plasticity. A novel
health tool that applies intelligent movement for
medical rehabilitation and to increase sports
performance. The biotech introduces strength as a
biometric tool in medicine.s

BUSINESS
MODEL
Manufacturing & sale of novel medical
treatment, novel neurodiagnostic
devices, and new medical technology are
key activities. Each subsidiary offers
propriety scientific discovery by
worldwide leaders in their field of
research whose innovation is validated
in value its role in advancing medicine.
The companies meet the demand of the
market seeking novel therapeutics and
the medical community's need for
increasing diagnostic capabilities.
PRODUCTS
1). (4) Four Regulated Drugs derived from cannabis for
cancer treatment, neurological illness, epilepsy and pain
management with proven efficacy in medical science
2). SaaS Detection of neurological & psychiatric illness
through a portable EEG device through AI translation of
brainwaves enabling in-office detection without needing
a neurologist or psychiatrist
 
3). Portable EEG Device for medical diagnostic of
neurological and psychiatric illness.
 
4). Physiotherahy equipment for Medical Rehabilitation ,
Sports Rehabilitation, and enhancing sports
performance for increasing neuronal plasticity through
integrating A.I and machine learning to analyze and
control  body movement
OUR ADVANTAGE
The power behind the acquisition targets/proposed subsidiaries
are their role in leading medical science research and how they
advance medicine. All companies possess proprietary
information through their scientific research which adds
significant value to their innovation via the direct role it plays in
advancing medicine.
$41,000,000
OFFERING
42,000,000 common
shares at .$50 per share
 (4) FOUR
SOURCES OF
REVENUE
ROYAL
SYNTHESIS
FORECASTED
NET REVENUE
AVERTUS
FORECASTED
NET REVENUE
NEUROMETRICS
FORECASTED
NET REVENUE
SYMCO 
FORECASTED
NET REVENUE
 MANAGEMENT TEAM
ERIKA JONES
FOUNDER & PRESIDENT
ERIKA is an entrepreneur, medical scientist and
artist. She completed her graduate studies in
Homeopathic Medicine and Medical Sciences
at Ontario College of Homeopathic Medicine in
Canada. She completed her thesis on the
hermetic effect in homeopathy where she
studied the toxicological phenomenon that
supports to support the mechanism within
homeopathy.. She is Phd Candidate at
University of Toronto through her research on
the biological complexities of the
endocannabiod system focusing on the role it
plays in maintaining health, in the pathological
process, and its role in developing medicine
derived from cannabis through in-vivo and in-
vitro research. She spends her spare time in
the arts, writing poetry or being creative
through a number of different mediums.
AZMATALI MEHRALI
CHIEF FINANCIAL OFFICER
Since 2006, Mr. Mehrali served as President of a
private CFO consulting business that provides
regulatory and finance services to start-up
brokerage firms in Canada. With over 30 years of
financial services experience, he has also been
CFO for several firms including Wells Fargo
Canada Securities, Brookfield Securities and
Virtual Brokers. He also served as Vice President,
Finance, at Genuity Capital Markets; Assistant
Controller, Investment Technology Group Canada;
Director of Finance, CIBC World Markets. Recently,
he has provided consulting services to start up
medicinal cannabis firms, assisting them as they
proceed with public listing.
 MANAGEMENT TEAM
DR. JEFFREY PETERSON
CHIEF MEDICAL SCIENCE OFFICER
Dr. Jeffrey D. Peterson has a PhD in Immunology
and Neuroscience and started his career spending
years researching a variety of autoimmune
diseases, including multiple sclerosis and Type I
diabetes.  He subsequently worked for ten years in
the Pharmaceutical and Biotech industry as a
Pharmacology researcher and Director, working to
discover novel drugs, therapies, and biomarkers
at companies such as Boehringer Ingelheim,
Curagen Corporation, Abbott Bioresearch Center,
and PerkinElmer Inc.  In this time, he developed
further expertise in a range of additional research
areas, including oncology, cardiovascular disease,
acute and chronic inflammation, arthritis,
pharmacokinetics, biodistribution, safety
pharmacology, and biomarker development.  He
has worked for the past 11 years in  developing
novel strategies for non-invasive assessment of
disease biology.
FODE TOURE
CHIEF TECHNOLOGY OFFICER
Mr. Touré obtained a PhD doctorate in computer
science from University of Montreal.  With over ten
years of experience in the Information Technology
field, Mr. Touré has served as Architect, Technology
Director, and CTO in several tech start-ups and
companies. He is the architect & Tech Lead behind
an innovative blockchain-based advertising
ecosystem and the subject-matter expert (SME) for
a blockchain-based multi-asset margin trading
crypto exchange. He has substantial expertise in
real-time & collaborative platforms, cloud
(AWS,Azure), AdTech, Blockchain, ML, AI, IoT, EdTech.
His scientific experiences and publications have
earned him numerous awards and scholarships in
more than one continent.  Mr. Touré is a
CertifiedBlockchain Solution Architect by
Blockchain Training Alliance and completed the
Blockchain Technologies: Business Innovation and
Application program from the MIT Sloan School of
Management.
MANAGEMENT TEAM
AZZA ABDALLAH
CHIEF LEGAL OFFICER

The expertise and specialty of Azza is regarding

securities law.  After receiving her LLB/JD in law
from York University and her LLB from University of
London & Council of Legal Education, she
continued her education at the Canadian Securities
Institute.  Her stellar work experience brings a
wealth of knowledge in corporate finance.  She
recently acted as Senior Vice President and Chief
Compliance Officer for both KPMG Corporate
Finance Inc and KPMG for which she also acted as
General Counsel.  Recently, she has made the
decision to work only part-time for KPMG due to
family obligations. Before working at KPMG, she
acted as Senior Vice President, Director, General
Counsel and Chief Compliance Officer for many
global financial corporations which include: Global
Maxfin Capital Corporation (IIROC Member) Global
Maxfin Investment Corporation (MFDA), Global
Growth Assets Inc. (OSC - Investment Fund
Manager), Global RESP Corporation (OSC) and
Global Insurance Solutions Inc.